Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
Top Cited Papers
- 1 July 2021
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 204 (1), 64-73
- https://doi.org/10.1164/rccm.202011-4153oc
Abstract
Rationale: Elexacaftor–tezacaftor–ivacaftor is a CFTR (cystic fibrosis [CF] transmembrane conductance regulator) modulator combination, developed for patients with CF with at least one Phe508del mutation. Objectives: To evaluate the effects of elexacaftor–tezacaftor– ivacaftor in patients with CF and advanced respiratory disease. Methods: A prospective observational study, including all patients aged ⩾12 years and with a percent-predicted FEV1 (ppFEV1) 1 = 29 (24–34). The mean (95% confidence interval) absolute increase in the ppFEV1 was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventilation, and/or enteral tube feeding decreased by 50%, 30%, and 50%, respectively (P < 0.01). Although 16 patients were on the transplant waiting list and 37 were undergoing transplantation evaluation at treatment initiation, only 2 received a transplant, and 1 died. By September 2020, only five patients were still on the transplantation path. Compared with the previous 2 years, a twofold decrease in the number of lung transplantations in patients with CF was observed in 2020, whereas the number of deaths without transplantation remained stable. Conclusions: In patients with advanced disease, elexacaftor–tezacaftor–ivacaftor is associated with rapid clinical improvement, often leading to the indication for lung transplantation being suspended.Keywords
This publication has 21 references indexed in Scilit:
- Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2020
- The future of cystic fibrosis care: a global perspectiveThe Lancet Respiratory Medicine, 2019
- Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del allelesERJ Open Research, 2019
- Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelinesJournal of Cystic Fibrosis, 2019
- ECFS best practice guidelines: the 2018 revisionJournal of Cystic Fibrosis, 2018
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delThe New England Journal of Medicine, 2017
- Cystic fibrosisThe Lancet, 2016
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRThe New England Journal of Medicine, 2015
- Future trends in cystic fibrosis demography in 34 European countriesEuropean Respiratory Journal, 2015
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011